Newsroom

Published in Frontiers in Stroke (June 2026), this study highlights the effects of DX243 in complementary in vitro and in vivo models of ischemic stroke.

• In cellular models replicating ischemic conditions, DX243 improves ATP levels following glutamate treatment in SH-SY5Y neuronal cell line and increases neuronal survival in primary cortical neurons subjected to oxygen-deprivation

• In a mouse model of stroke (middle cerebral artery occlusion-MCAO), a single injection of DX243 administered at the time of reperfusion significantly reduces cerebral infarct volume and preserves motor coordination assessed 48 hours after the stroke.

• At the tissue level, treatment is associated with reduced neuronal loss and increased synaptic marker expression in the ischemic hemisphere.

These results provide an initial proof of concept for supporting DX243 as a promising candidate for protecting brain function after ischemic stroke, warranting further preclinical and clinical investigations.

👉Read here : Beneficial effects of the novel first-in-class compound DX243 on ischemic outcomes following in vitro and in vivo models of stroke.